Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (9): 918-924.DOI: 10.3969/j.issn.1673-8640.2025.09.016

Previous Articles     Next Articles

Status of clinical research on pancreatic enzyme markers

CHEN Fujun, CHEN Maoming   

  1. TOKYO Biomedical Pharma Co.,Ltd.,Tokyo 285-0922,Japan
  • Received:2024-08-28 Revised:2024-11-19 Online:2025-09-30 Published:2025-09-30

Abstract:

The pancreas is one of the important digestive organs in the human body. The enzymes secreted by it can be classified into carbohydrate-degrading enzymes [such as amylase (AMY),maltase],protein-degrading enzymes (trypsin,elastase,chymotrypsin,carboxypeptidase A,carboxypeptidase B) and fat-degrading enzymes [lipase (LPS),phospholipase A2 (PLA2)]. Currently,pancreatic enzymes like AMY and LPS have been widely used as biomarkers for pancreatic-related diseases in clinical practice. Serum elastase 1 not only has significant reference value for the diagnosis of acute and chronic pancreatitis,but also,when combined with tumor markers,can significantly increase the positive determination rate of early pancreatic cancer (early pancreatic head cancer). Moreover,elastase 1 in fecal samples can be used as a biomarker for evaluating pancreatic exocrine function. Serum trypsin can be used to predict pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP),and its predictive efficacy is superior to AMY. This review presents the current clinical research status of main pancreatic enzyme markers such as AMY,LPS,trypsin and elastase,and focuses on summarizing the clinical research progress of elastase 1 and trypsin,providing references for clinical diagnosis of pancreatic diseases and assessment of pancreatic exocrine function.

Key words: Pancreatic enzyme marker, Elastase 1, Trypsin, Amylase, Lipase

CLC Number: